Skip to main content
Top
Published in: Cellular Oncology 6/2014

01-12-2014 | Original Paper

Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients

Authors: Andrea Bandino, Dirk Geerts, Jan Koster, André S. Bachmann

Published in: Cellular Oncology | Issue 6/2014

Login to get access

Abstract

Purpose

Neuroblastoma (NB) is an aggressive pediatric malignancy that typically occurs in infants and children under the age of 5 years. High-stage tumors relapse frequently even after aggressive multimodal treatment, resulting in therapy resistance and eventually in patient death. Clearly, new biologically-targeted drugs are needed that more efficiently suppress tumor growth and prevent relapse. We and others previously showed that polyamines such as spermidine play an essential role in NB tumorigenesis and that DFMO, an inhibitor of the central polyamine synthesis gene ODC, is effective in vitro and in vivo, prompting its evaluation in NB clinical trials. However, the specific molecular actions of polyamines remain poorly defined. Spermidine and deoxyhypusine synthase (DHPS) are essential components in the hypusination-driven post-translational activation of eukaryotic initiation factor 5A (eIF5A).

Methods

We assessed the role of DHPS in NB and the impact of its inhibition by N 1 -guanyl-1,7-diaminoheptane (GC7) on tumor cell growth using cell proliferation assays, Western blot, immunofluorescence microscopy, and Affymetrix micro-array mRNA expression analyses in NB tumor samples.

Results

We found that GC7 inhibits NB cell proliferation in a dose-dependent manner, through induction of the cell cycle inhibitor p21 and reduction of total and phosphorylated Rb proteins. Strikingly, high DHPS mRNA expression correlated significantly with unfavorable clinical parameters, including poor patient survival, in a cohort of 88 NB tumors (all P < 0.04).

Conclusions

These results suggest that spermidine and DHPS are key contributing factors in NB tumor proliferation through regulation of the p21/Rb signaling axis.
Literature
1.
go back to reference G.M. Brodeur, Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3, 203–216 (2003)PubMedCrossRef G.M. Brodeur, Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3, 203–216 (2003)PubMedCrossRef
2.
go back to reference N.K. Cheung, M.A. Dyer, Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 13, 397–411 (2013)PubMedCrossRef N.K. Cheung, M.A. Dyer, Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 13, 397–411 (2013)PubMedCrossRef
4.
go back to reference J.M. Maris, M.D. Hogarty, R. Bagatell, S.L. Cohn, Neuroblastoma Lancet 369, 2106–2120 (2007)CrossRef J.M. Maris, M.D. Hogarty, R. Bagatell, S.L. Cohn, Neuroblastoma Lancet 369, 2106–2120 (2007)CrossRef
5.
go back to reference J.R. Park, A. Eggert, H. Caron, Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 24, 65–86 (2010)PubMedCrossRef J.R. Park, A. Eggert, H. Caron, Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 24, 65–86 (2010)PubMedCrossRef
6.
go back to reference M. Schwab, F. Westermann, B. Hero, F. Berthold, Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4, 472–480 (2003)PubMedCrossRef M. Schwab, F. Westermann, B. Hero, F. Berthold, Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4, 472–480 (2003)PubMedCrossRef
7.
go back to reference D.L. Baker, M.L. Schmidt, S.L. Cohn, J.M. Maris, W.B. London, A. Buxton, D. Stram, R.P. Castleberry, H. Shimada, A. Sandler, R.C. Shamberger, A.T. Look, C.P. Reynolds, R.C. Seeger, K.K. Matthay, G. Children’s Oncology, Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363, 1313–1323 (2010)PubMedCentralPubMedCrossRef D.L. Baker, M.L. Schmidt, S.L. Cohn, J.M. Maris, W.B. London, A. Buxton, D. Stram, R.P. Castleberry, H. Shimada, A. Sandler, R.C. Shamberger, A.T. Look, C.P. Reynolds, R.C. Seeger, K.K. Matthay, G. Children’s Oncology, Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363, 1313–1323 (2010)PubMedCentralPubMedCrossRef
8.
go back to reference S.L. Cohn, A.D. Pearson, W.B. London, T. Monclair, P.F. Ambros, G.M. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, V. Mosseri, T. Simon, A. Garaventa, V. Castel, K.K. Matthay, The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol 27, 289–297 (2009)PubMedCentralPubMedCrossRef S.L. Cohn, A.D. Pearson, W.B. London, T. Monclair, P.F. Ambros, G.M. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, V. Mosseri, T. Simon, A. Garaventa, V. Castel, K.K. Matthay, The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol 27, 289–297 (2009)PubMedCentralPubMedCrossRef
9.
go back to reference S.G. Kreissman, R.C. Seeger, K.K. Matthay, W.B. London, R. Sposto, S.A. Grupp, D.A. Haas-Kogan, M.P. Laquaglia, A.L. Yu, L. Diller, A. Buxton, J.R. Park, S.L. Cohn, J.M. Maris, C.P. Reynolds, J.G. Villablanca, Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14, 999–1008 (2013)PubMedCentralPubMedCrossRef S.G. Kreissman, R.C. Seeger, K.K. Matthay, W.B. London, R. Sposto, S.A. Grupp, D.A. Haas-Kogan, M.P. Laquaglia, A.L. Yu, L. Diller, A. Buxton, J.R. Park, S.L. Cohn, J.M. Maris, C.P. Reynolds, J.G. Villablanca, Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14, 999–1008 (2013)PubMedCentralPubMedCrossRef
10.
go back to reference D.R. Strother, W.B. London, M.L. Schmidt, G.M. Brodeur, H. Shimada, P. Thorner, M.H. Collins, E. Tagge, S. Adkins, C.P. Reynolds, K. Murray, R.S. Lavey, K.K. Matthay, R. Castleberry, J.M. Maris, S.L. Cohn, Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of children’s oncology group study P9641. J Clin Oncol 30, 1842–1848 (2012)PubMedCentralPubMedCrossRef D.R. Strother, W.B. London, M.L. Schmidt, G.M. Brodeur, H. Shimada, P. Thorner, M.H. Collins, E. Tagge, S. Adkins, C.P. Reynolds, K. Murray, R.S. Lavey, K.K. Matthay, R. Castleberry, J.M. Maris, S.L. Cohn, Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of children’s oncology group study P9641. J Clin Oncol 30, 1842–1848 (2012)PubMedCentralPubMedCrossRef
11.
go back to reference A. Canete, M. Gerrard, H. Rubie, V. Castel, A. Di Cataldo, C. Munzer, R. Ladenstein, B. Brichard, J.D. Bermudez, J. Couturier, B. de Bernardi, A.J. Pearson, J. Michon, Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the international society of paediatric oncology European neuroblastoma experience. J Clin Oncol 27, 1014–1019 (2009)PubMedCrossRef A. Canete, M. Gerrard, H. Rubie, V. Castel, A. Di Cataldo, C. Munzer, R. Ladenstein, B. Brichard, J.D. Bermudez, J. Couturier, B. de Bernardi, A.J. Pearson, J. Michon, Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the international society of paediatric oncology European neuroblastoma experience. J Clin Oncol 27, 1014–1019 (2009)PubMedCrossRef
12.
go back to reference B.H. Kushner, K. Kramer, M.P. LaQuaglia, S. Modak, K. Yataghene, N.K. Cheung, Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 22, 4888–4892 (2004)PubMedCrossRef B.H. Kushner, K. Kramer, M.P. LaQuaglia, S. Modak, K. Yataghene, N.K. Cheung, Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 22, 4888–4892 (2004)PubMedCrossRef
13.
go back to reference A.S. Bachmann, The role of polyamines in human cancer: prospects for drug combination therapies. Hawaii Med J 63, 371–374 (2004)PubMed A.S. Bachmann, The role of polyamines in human cancer: prospects for drug combination therapies. Hawaii Med J 63, 371–374 (2004)PubMed
14.
go back to reference R.A. Casero Jr., L.J. Marton, Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6, 373–390 (2007)PubMedCrossRef R.A. Casero Jr., L.J. Marton, Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6, 373–390 (2007)PubMedCrossRef
15.
go back to reference A.E. Pegg, Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 48, 759–774 (1988)PubMed A.E. Pegg, Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 48, 759–774 (1988)PubMed
16.
17.
go back to reference E.W. Gerner, F.L. Meyskens Jr., Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4, 781–792 (2004)PubMedCrossRef E.W. Gerner, F.L. Meyskens Jr., Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4, 781–792 (2004)PubMedCrossRef
18.
go back to reference D.L. Koomoa, L.P. Yco, T. Borsics, C.J. Wallick, A.S. Bachmann, Ornithine decarboxylase inhibition by {alpha}-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/Protein Kinase B and p27Kip1 in Neuroblastoma. Cancer Res 68, 9825–9831 (2008)PubMedCentralPubMedCrossRef D.L. Koomoa, L.P. Yco, T. Borsics, C.J. Wallick, A.S. Bachmann, Ornithine decarboxylase inhibition by {alpha}-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/Protein Kinase B and p27Kip1 in Neuroblastoma. Cancer Res 68, 9825–9831 (2008)PubMedCentralPubMedCrossRef
19.
go back to reference C.J. Wallick, I. Gamper, M. Thorne, D.J. Feith, K.Y. Takasaki, S.M. Wilson, J.A. Seki, A.E. Pegg, C.V. Byus, A.S. Bachmann, Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24, 5606–5618 (2005)PubMedCrossRef C.J. Wallick, I. Gamper, M. Thorne, D.J. Feith, K.Y. Takasaki, S.M. Wilson, J.A. Seki, A.E. Pegg, C.V. Byus, A.S. Bachmann, Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24, 5606–5618 (2005)PubMedCrossRef
20.
go back to reference D.L. Koomoa, T. Borsics, D.J. Feith, C.C. Coleman, C.J. Wallick, I. Gamper, A.E. Pegg, A.S. Bachmann, Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma. Mol Cancer Ther 8, 2067–2075 (2009)PubMedCentralPubMedCrossRef D.L. Koomoa, T. Borsics, D.J. Feith, C.C. Coleman, C.J. Wallick, I. Gamper, A.E. Pegg, A.S. Bachmann, Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma. Mol Cancer Ther 8, 2067–2075 (2009)PubMedCentralPubMedCrossRef
21.
go back to reference D.L. Koomoa, D. Geerts, I. Lange, J. Koster, A.E. Pegg, D.J. Feith, A.S. Bachmann, DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 42, 1219–1228 (2013)PubMedCentralPubMed D.L. Koomoa, D. Geerts, I. Lange, J. Koster, A.E. Pegg, D.J. Feith, A.S. Bachmann, DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 42, 1219–1228 (2013)PubMedCentralPubMed
22.
go back to reference K. Samal, P. Zhao, A. Kendzicky, L.P. Yco, H. McClung, E. Gerner, M. Burns, A.S. Bachmann, G. Sholler, AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer 133, 1323–1333 (2013)PubMedCrossRef K. Samal, P. Zhao, A. Kendzicky, L.P. Yco, H. McClung, E. Gerner, M. Burns, A.S. Bachmann, G. Sholler, AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer 133, 1323–1333 (2013)PubMedCrossRef
23.
go back to reference M.D. Hogarty, M.D. Norris, K. Davis, X. Liu, N.F. Evageliou, C.S. Hayes, B. Pawel, R. Guo, H. Zhao, E. Sekyere, J. Keating, W. Thomas, N.C. Cheng, J. Murray, J. Smith, R. Sutton, N. Venn, W.B. London, A. Buxton, S.K. Gilmour, G.M. Marshall, M. Haber, ODC1 Is a critical determinant of MYCN Oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68, 9735–9745 (2008)PubMedCentralPubMedCrossRef M.D. Hogarty, M.D. Norris, K. Davis, X. Liu, N.F. Evageliou, C.S. Hayes, B. Pawel, R. Guo, H. Zhao, E. Sekyere, J. Keating, W. Thomas, N.C. Cheng, J. Murray, J. Smith, R. Sutton, N. Venn, W.B. London, A. Buxton, S.K. Gilmour, G.M. Marshall, M. Haber, ODC1 Is a critical determinant of MYCN Oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68, 9735–9745 (2008)PubMedCentralPubMedCrossRef
24.
go back to reference R.J. Rounbehler, W. Li, M.A. Hall, C. Yang, M. Fallahi, J.L. Cleveland, Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69, 547–553 (2009)PubMedCentralPubMedCrossRef R.J. Rounbehler, W. Li, M.A. Hall, C. Yang, M. Fallahi, J.L. Cleveland, Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69, 547–553 (2009)PubMedCentralPubMedCrossRef
25.
go back to reference G. Sholler, E. Currier, D.L. Koomoa, A.S. Bachmann, synergistic inhibition of neuroblastoma tumor development by targeting ornithine decarboxylase and topoisomerase II. In 14th Advances in Neuroblastoma Research (ANR) Conference, Stockholm, Sweden, POT74 (2010) G. Sholler, E. Currier, D.L. Koomoa, A.S. Bachmann, synergistic inhibition of neuroblastoma tumor development by targeting ornithine decarboxylase and topoisomerase II. In 14th Advances in Neuroblastoma Research (ANR) Conference, Stockholm, Sweden, POT74 (2010)
26.
go back to reference G. Sholler, E. Gerner, G. Bergendahl, B.J. LaFleur, A. VanderWerff, T. Ashilkaga, W. Ferguson, W. Roberts, R.K. Wada, D. Eslin, J. Kraveka, J. Kaplan, D. Mitchell, N.S. Parikh, K. Neville, L. Sender, T. Higgins, M. Kawakita, K. Hiramatsu, S.S. Moriya, A.S. Bachmann, A phase I trial of DFMO as a single agent and in combination with etoposide in patients with refractory or recurrent neuroblastoma. In Annual Meeting of the American Association for Cancer Research (AACR), Washington, D.C., LB-179 (2013) G. Sholler, E. Gerner, G. Bergendahl, B.J. LaFleur, A. VanderWerff, T. Ashilkaga, W. Ferguson, W. Roberts, R.K. Wada, D. Eslin, J. Kraveka, J. Kaplan, D. Mitchell, N.S. Parikh, K. Neville, L. Sender, T. Higgins, M. Kawakita, K. Hiramatsu, S.S. Moriya, A.S. Bachmann, A phase I trial of DFMO as a single agent and in combination with etoposide in patients with refractory or recurrent neuroblastoma. In Annual Meeting of the American Association for Cancer Research (AACR), Washington, D.C., LB-179 (2013)
27.
go back to reference A.S. Bachmann, D. Geerts, G. Sholler, Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. In Pediatric Cancer, Neuroblastoma: Diagnosis, Therapy, and Prognosis, ed. by M.A. Hayat, Springer Publisher, 91–103 (2012) A.S. Bachmann, D. Geerts, G. Sholler, Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. In Pediatric Cancer, Neuroblastoma: Diagnosis, Therapy, and Prognosis, ed. by M.A. Hayat, Springer Publisher, 91–103 (2012)
28.
go back to reference A.S. Bachmann, V.A. Levin, Clinical applications of polyamine-based therapeutics. In Polyamine Drug Discovery, ed. by P.M. Woster and R.A. Casero, Jr., Royal Society of Chemistry, 257–276 (2012) A.S. Bachmann, V.A. Levin, Clinical applications of polyamine-based therapeutics. In Polyamine Drug Discovery, ed. by P.M. Woster and R.A. Casero, Jr., Royal Society of Chemistry, 257–276 (2012)
29.
go back to reference U. Bachrach, Naturally occurring polyamines: interaction with macromolecules. Curr Protein Pept Sci 6, 559–566 (2005)PubMedCrossRef U. Bachrach, Naturally occurring polyamines: interaction with macromolecules. Curr Protein Pept Sci 6, 559–566 (2005)PubMedCrossRef
32.
go back to reference M.H. Park, K. Nishimura, C.F. Zanelli, S.R. Valentini, Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 38, 491–500 (2010)PubMedCentralPubMedCrossRef M.H. Park, K. Nishimura, C.F. Zanelli, S.R. Valentini, Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 38, 491–500 (2010)PubMedCentralPubMedCrossRef
33.
go back to reference E.A. Paz, B. LaFleur, E.W. Gerner, Polyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells. Mol Carcinog 53(Suppl 1), E96–106 (2014)PubMedCrossRef E.A. Paz, B. LaFleur, E.W. Gerner, Polyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells. Mol Carcinog 53(Suppl 1), E96–106 (2014)PubMedCrossRef
34.
go back to reference E.W. Gerner, Cancer chemoprevention locks onto a new polyamine metabolic target. Cancer Prev Res 3, 125–127 (2010)CrossRef E.W. Gerner, Cancer chemoprevention locks onto a new polyamine metabolic target. Cancer Prev Res 3, 125–127 (2010)CrossRef
35.
go back to reference J. Jakus, E.C. Wolff, M.H. Park, J.E. Folk, Features of the spermidine-binding site of deoxyhypusine synthase as derived from inhibition studies. Effective inhibition by bis- and mono-guanylated diamines and polyamines. J Biol Chem 268, 13151–13159 (1993)PubMed J. Jakus, E.C. Wolff, M.H. Park, J.E. Folk, Features of the spermidine-binding site of deoxyhypusine synthase as derived from inhibition studies. Effective inhibition by bis- and mono-guanylated diamines and polyamines. J Biol Chem 268, 13151–13159 (1993)PubMed
36.
go back to reference M.H. Park, E.C. Wolff, Y.B. Lee, J.E. Folk, Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J Biol Chem 269, 27827–27832 (1994)PubMed M.H. Park, E.C. Wolff, Y.B. Lee, J.E. Folk, Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J Biol Chem 269, 27827–27832 (1994)PubMed
37.
go back to reference Y. Lee, H.K. Kim, H.E. Park, M.H. Park, Y.A. Joe, Effect of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on endothelial cell growth, differentiation and apoptosis. Mol Cell Biochem 237, 69–76 (2002)PubMedCrossRef Y. Lee, H.K. Kim, H.E. Park, M.H. Park, Y.A. Joe, Effect of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on endothelial cell growth, differentiation and apoptosis. Mol Cell Biochem 237, 69–76 (2002)PubMedCrossRef
38.
go back to reference A. Slack, Z. Chen, R. Tonelli, M. Pule, L. Hunt, A. Pession, J.M. Shohet, The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 102, 731–736 (2005)PubMedCentralPubMedCrossRef A. Slack, Z. Chen, R. Tonelli, M. Pule, L. Hunt, A. Pession, J.M. Shohet, The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 102, 731–736 (2005)PubMedCentralPubMedCrossRef
39.
go back to reference P. Fardin, A. Barla, S. Mosci, L. Rosasco, A. Verri, R. Versteeg, H.N. Caron, J.J. Molenaar, I. Ora, A. Eva, M. Puppo, L. Varesio, A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer 9, 185 (2010)PubMedCentralPubMedCrossRef P. Fardin, A. Barla, S. Mosci, L. Rosasco, A. Verri, R. Versteeg, H.N. Caron, J.J. Molenaar, I. Ora, A. Eva, M. Puppo, L. Varesio, A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer 9, 185 (2010)PubMedCentralPubMedCrossRef
40.
go back to reference I. Revet, G. Huizenga, A. Chan, J. Koster, R. Volckmann, P. van Sluis, I. Ora, R. Versteeg, D. Geerts, The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res 314, 707–719 (2008)PubMedCrossRef I. Revet, G. Huizenga, A. Chan, J. Koster, R. Volckmann, P. van Sluis, I. Ora, R. Versteeg, D. Geerts, The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res 314, 707–719 (2008)PubMedCrossRef
41.
go back to reference T. Barrett, D.B. Troup, S.E. Wilhite, P. Ledoux, D. Rudnev, C. Evangelista, I.F. Kim, A. Soboleva, M. Tomashevsky, K.A. Marshall, K.H. Phillippy, P.M. Sherman, R.N. Muertter, R. Edgar, NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 37, D885–890 (2009)PubMedCentralPubMedCrossRef T. Barrett, D.B. Troup, S.E. Wilhite, P. Ledoux, D. Rudnev, C. Evangelista, I.F. Kim, A. Soboleva, M. Tomashevsky, K.A. Marshall, K.H. Phillippy, P.M. Sherman, R.N. Muertter, R. Edgar, NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 37, D885–890 (2009)PubMedCentralPubMedCrossRef
43.
go back to reference T. Borsics, E. Lundberg, D. Geerts, D.L. Koomoa, J. Koster, K. Wester, A.S. Bachmann, Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: influence on cell survival and migration. Cancer Sci 101, 1624–1631 (2010)PubMedCrossRef T. Borsics, E. Lundberg, D. Geerts, D.L. Koomoa, J. Koster, K. Wester, A.S. Bachmann, Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: influence on cell survival and migration. Cancer Sci 101, 1624–1631 (2010)PubMedCrossRef
44.
go back to reference J.E. Gawecka, D. Geerts, J. Koster, M.J. Caliva, F.J. Sulzmaier, J. Opoku-Ansah, R.K. Wada, A.S. Bachmann, J.W. Ramos, PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer 131, 1556–1568 (2012)PubMedCentralPubMedCrossRef J.E. Gawecka, D. Geerts, J. Koster, M.J. Caliva, F.J. Sulzmaier, J. Opoku-Ansah, R.K. Wada, A.S. Bachmann, J.W. Ramos, PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer 131, 1556–1568 (2012)PubMedCentralPubMedCrossRef
45.
go back to reference D. Geerts, J. Koster, D. Albert, D.L. Koomoa, D.J. Feith, A.E. Pegg, R. Volckmann, H. Caron, R. Versteeg, A.S. Bachmann, The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 126, 2012–2024 (2010)PubMedCentralPubMed D. Geerts, J. Koster, D. Albert, D.L. Koomoa, D.J. Feith, A.E. Pegg, R. Volckmann, H. Caron, R. Versteeg, A.S. Bachmann, The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 126, 2012–2024 (2010)PubMedCentralPubMed
46.
go back to reference D. Geerts, C.J. Wallick, D.L. Koomoa, J. Koster, R. Versteeg, R.C. Go, A.S. Bachmann, Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Clin Cancer Res 13, 6312–6319 (2007)PubMedCrossRef D. Geerts, C.J. Wallick, D.L. Koomoa, J. Koster, R. Versteeg, R.C. Go, A.S. Bachmann, Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Clin Cancer Res 13, 6312–6319 (2007)PubMedCrossRef
47.
go back to reference I. Lange, D. Geerts, D.J. Feith, G. Mocz, J. Koster, A.S. Bachmann, Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. J Mol Biol 426, 332–346 (2014)PubMedCrossRef I. Lange, D. Geerts, D.J. Feith, G. Mocz, J. Koster, A.S. Bachmann, Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. J Mol Biol 426, 332–346 (2014)PubMedCrossRef
48.
go back to reference L.P. Yco, D. Geerts, J. Koster, A.S. Bachmann, PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. Int J Oncol 42, 1408–1416 (2013)PubMed L.P. Yco, D. Geerts, J. Koster, A.S. Bachmann, PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. Int J Oncol 42, 1408–1416 (2013)PubMed
49.
go back to reference C. Scuoppo, C. Miething, L. Lindqvist, J. Reyes, C. Ruse, I. Appelmann, S. Yoon, A. Krasnitz, J. Teruya-Feldstein, D. Pappin, J. Pelletier, S.W. Lowe, A tumour suppressor network relying on the polyamine-hypusine axis. Nature 487, 244–248 (2012)PubMedCentralPubMedCrossRef C. Scuoppo, C. Miething, L. Lindqvist, J. Reyes, C. Ruse, I. Appelmann, S. Yoon, A. Krasnitz, J. Teruya-Feldstein, D. Pappin, J. Pelletier, S.W. Lowe, A tumour suppressor network relying on the polyamine-hypusine axis. Nature 487, 244–248 (2012)PubMedCentralPubMedCrossRef
50.
go back to reference J. Lu, Z.P. Chen, Y.P. Yan, S. Knapp, H. Schugar, K.Y. Chen, Aminohexanoic hydroxamate is a potent inducer of the differentiation of mouse neuroblastoma cells. Cancer Lett 160, 59–66 (2000)PubMedCrossRef J. Lu, Z.P. Chen, Y.P. Yan, S. Knapp, H. Schugar, K.Y. Chen, Aminohexanoic hydroxamate is a potent inducer of the differentiation of mouse neuroblastoma cells. Cancer Lett 160, 59–66 (2000)PubMedCrossRef
51.
go back to reference A.D. Luchessi, T.D. Cambiaghi, S.M. Hirabara, R.H. Lambertucci, L.R. Silveira, I.L. Baptista, A.S. Moriscot, C.M. Costa-Neto, R. Curi, Involvement of eukaryotic translation initiation factor 5A (eIF5A) in skeletal muscle stem cell differentiation. J Cell Physiol 218, 480–489 (2009)PubMedCrossRef A.D. Luchessi, T.D. Cambiaghi, S.M. Hirabara, R.H. Lambertucci, L.R. Silveira, I.L. Baptista, A.S. Moriscot, C.M. Costa-Neto, R. Curi, Involvement of eukaryotic translation initiation factor 5A (eIF5A) in skeletal muscle stem cell differentiation. J Cell Physiol 218, 480–489 (2009)PubMedCrossRef
52.
go back to reference M. Preukschas, C. Hagel, A. Schulte, K. Weber, K. Lamszus, H. Sievert, N. Pallmann, C. Bokemeyer, J. Hauber, M. Braig, S. Balabanov, Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. PLoS One 7, e43468 (2012)PubMedCentralPubMedCrossRef M. Preukschas, C. Hagel, A. Schulte, K. Weber, K. Lamszus, H. Sievert, N. Pallmann, C. Bokemeyer, J. Hauber, M. Braig, S. Balabanov, Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. PLoS One 7, e43468 (2012)PubMedCentralPubMedCrossRef
53.
go back to reference J.J. Molenaar, R. Domingo-Fernandez, M.E. Ebus, S. Lindner, J. Koster, K. Drabek, P. Mestdagh, P. van Sluis, L.J. Valentijn, J. van Nes, M. Broekmans, F. Haneveld, R. Volckmann, I. Bray, L. Heukamp, A. Sprussel, T. Thor, K. Kieckbusch, L. Klein-Hitpass, M. Fischer, J. Vandesompele, A. Schramm, M.M. van Noesel, L. Varesio, F. Speleman, A. Eggert, R.L. Stallings, H.N. Caron, R. Versteeg, J.H. Schulte, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44, 1199–1206 (2012)PubMedCrossRef J.J. Molenaar, R. Domingo-Fernandez, M.E. Ebus, S. Lindner, J. Koster, K. Drabek, P. Mestdagh, P. van Sluis, L.J. Valentijn, J. van Nes, M. Broekmans, F. Haneveld, R. Volckmann, I. Bray, L. Heukamp, A. Sprussel, T. Thor, K. Kieckbusch, L. Klein-Hitpass, M. Fischer, J. Vandesompele, A. Schramm, M.M. van Noesel, L. Varesio, F. Speleman, A. Eggert, R.L. Stallings, H.N. Caron, R. Versteeg, J.H. Schulte, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44, 1199–1206 (2012)PubMedCrossRef
Metadata
Title
Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients
Authors
Andrea Bandino
Dirk Geerts
Jan Koster
André S. Bachmann
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 6/2014
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-014-0201-9

Other articles of this Issue 6/2014

Cellular Oncology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine